Injectafer ferric carboxymaltose regulatory update

Daiichi's Luitpold Pharmaceuticals Inc. unit said CMS issued a Q-code for reimbursement of Injectafer ferric carboxymaltose to treat iron deficiency anemia. The code, Q9970, will become effective on July 1. Last July, FDA approved a resubmitted NDA for Injectafer for use in adults who have not responded to or are intolerant to oral iron, as well as for adults with non-dialysis dependent chronic kidney disease (CKD). Luitpold has U.S. rights to the non-dextran IV iron replacement from Galenica. ...